1. Report Introduction 2. Acute Myeloid Leukemia (AML) Market Overview at a Glance 2.1. Market Share Distribution of Acute Myeloid Leukemia (AML) in 2016 2.2. Market Share Distribution of Acute Myeloid Leukemia (AML) in 2028 3. Disease Background and Overview: Acute Myeloid Leukemia (AML) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Acute Myeloid Leukemia (AML) in 7MM 4.3. Total Prevalent Patient Population of Acute Myeloid Leukemia (AML) in 7MM – By Countries 5. Epidemiology of Acute Myeloid Leukemia (AML) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.1.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.1.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.1.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.1.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.4.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.4.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.4.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.4.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.5.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.5.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.5.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.5.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.6.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.6.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.6.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.6.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.7.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.7.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.7.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.7.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.8.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.8.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.8.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.8.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) 5.9.3. Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) * 5.9.4. Sex- Specific Cases of the Acute Myeloid Leukemia (AML) * 5.9.5. Diagnosed Cases of the Acute Myeloid Leukemia (AML) 5.9.6. Treatable Cases of the Acute Myeloid Leukemia (AML) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Acute Myeloid Leukemia (AML) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Acute Myeloid Leukemia (AML) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Acute Myeloid Leukemia (AML) : 7MM Market Analysis 12.1. 7MM Market Size of Acute Myeloid Leukemia (AML) 12.2. 7MM Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) 12.3. 7MM Market Sales of Acute Myeloid Leukemia (AML) by Products 13. Acute Myeloid Leukemia (AML) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Acute Myeloid Leukemia (AML) in United States 13.1.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in United States 13.1.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Acute Myeloid Leukemia (AML) in Germany 13.2.1.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in Germany 13.2.1.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Acute Myeloid Leukemia (AML) in France 13.2.2.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in France 13.2.2.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Acute Myeloid Leukemia (AML) in Italy 13.2.3.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in Italy 13.2.3.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Acute Myeloid Leukemia (AML) in Spain 13.2.4.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in Spain 13.2.4.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Acute Myeloid Leukemia (AML) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in United Kingdom 13.2.5.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Acute Myeloid Leukemia (AML) in Japan 13.3.2. Percentage Share of drugs marketed for Acute Myeloid Leukemia (AML) in Japan 13.3.3. Market Sales of Acute Myeloid Leukemia (AML) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM Table 2: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Table 5: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Table 6: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Table 7: Treatable Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Table 11: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Table 12: Treatable Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Table 14: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Table 15: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Table 16: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Table 17: Treatable Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Table 21: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Table 22: Treatable Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Table 26: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Table 27: Treatable Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Table 30: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Table 31: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Table 32: Treatable Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Table 36: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Table 37: Treatable Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 42:7MM- Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 45: United States-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 48: Germany-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 51: France-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 54: Italy-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 57: Spain-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 60:UK-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Table 63: Japan-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM Figure 2: Total Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Figure 6: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Figure 7: Treatable Cases of the Acute Myeloid Leukemia (AML) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Figure 12: Treatable Cases of the Acute Myeloid Leukemia (AML) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Figure 15: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Figure 16: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Figure 17: Treatable Cases of the Acute Myeloid Leukemia (AML) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Figure 22: Treatable Cases of the Acute Myeloid Leukemia (AML) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Figure 27: Treatable Cases of the Acute Myeloid Leukemia (AML) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Figure 31: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Figure 32: Treatable Cases of the Acute Myeloid Leukemia (AML) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Figure 37: Treatable Cases of the Acute Myeloid Leukemia (AML) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 42:7MM- Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 45: United States-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 48: Germany-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 51: France-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 54: Italy-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 57: Spain-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 60:UK-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Acute Myeloid Leukemia (AML) in USD MM (2016-2028) Figure 63: Japan-Market Share Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Acute Myeloid Leukemia (AML) by Therapies in USD MM (2016-2028)